Investigational drug · Phase 3
ESA
Also called: Erythropoiesis-Stimulating Agent
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anemia Due to Chronic Kidney Disease, Anemia of Chronic Kidney Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
150
Any phase or sponsor naming "ESA"
First trial start
2025
Jul 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ESA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anemia Due to Chronic Kidney Disease
- Anemia of Chronic Kidney Disease
Approved drugs for the same conditions: Anemia · Chronic kidney disease · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ESA" as an intervention, largest first.
- The Cancer of the Pancreas Screening-5 CAPS5)StudyPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT02000089 · 9,000 participants (planned) · Start Jan 6, 2014 · Primary completion Dec 2028
Drug: Secretin · For: Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation and 2 more
Sites: New Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 9 sites in all
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02876835 · 3,872 participants · Start Sep 27, 2016 · Primary completion Apr 19, 2021
Drug: Daprodustat; Darbepoetin alfa and 2 more · For: Anaemia
Sites: Andalusia, Alabama; Birmingham, Alabama; Huntsville, Alabama · 574 sites in all
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02879305 · 2,964 participants · Start Sep 28, 2016 · Primary completion Nov 9, 2020
Drug: Daprodustat; rhEPO and 2 more · For: Anaemia; Aspergillosis, Allergic Bronchopulmonary
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Anaheim, California · 462 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00773513 · 2,825 participants · Start Dec 12, 2008 · Primary completion Jul 27, 2017
Drug: Darbepoetin Alfa; Epoetin Alfa and 2 more · For: Chronic Renal Anemia
Sites: Buenos Aires, Argentina; CABA, Argentina; Gosford, Australia · 196 sites in all
- Vafseo Outcomes In-Center ExperiencePivotal-lookingCompleted
USRC Kidney ResearchResearch network
NCT06520826 · 2,116 participants · Start Nov 20, 2024 · Primary completion Sep 10, 2026
Drug: Vadadustat; Erythropoiesis Stimulating Agent · For: Anemia of Chronic Kidney Disease
Sites: Lone Tree, Colorado; Dalton, Georgia; Gallup, New Mexico · 5 sites in all
- A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard ChemotherapyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00338286 · 2,098 participants · Start Mar 2, 2006 · Primary completion Jul 7, 2014
Drug: epoetin alfa + packed RBC transfusion · For: Breast Cancer; Neoplasm Metastasis
Sites: Anaheim, California; Gainesville, Florida; Miami, Florida · 174 sites in all
- Connect® Myeloid Disease RegistryTerminated
CelgeneBristol Myers Squibb (BMY)
NCT01688011 · 2,013 participants · Start Dec 12, 2013 · Primary completion Oct 18, 2024
Drug: Luspatercept · For: Primary Myelofibrosis; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Tucson, Arizona · 158 sites in all
- A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal AnemiaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00090753 · 1,228 participants · Start Oct 2004 · Primary completion Dec 2009
Drug: Methoxy Polyethylene Glycol-Epoetin Beta; Epoetin alfa and 2 more · For: Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 249 sites in all
- Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable DialysisPivotal-lookingCompleted
Astellas Pharma Europe B.V.Astellas (ALPMY)
NCT02278341 · 838 participants · Start Nov 21, 2014 · Primary completion Jun 8, 2017
Drug: Roxadustat; Epoetin alfa and 2 more · For: Anemia; End Stage Renal Disease (ESRD)
Sites: Brussels, Belgium; Aalst, Belgium; Antwerp, Belgium · 143 sites in all
- Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on HemodialysisPivotal-lookingCompleted
AffymaxIndustry
NCT00597584 · 823 participants · Start Oct 2007 · Primary completion Jul 2009
Drug: peginesatide; Epoetin alfa or Epoetin beta · For: Chronic Renal Failure; Chronic Kidney Disease; Anemia
Sites: Phoenix, Arizona; Hot Springs, Arkansas; McGehee, Arkansas · 84 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Quorum sensing-driven riboflavin-hyperproducing electroactive bacteria for enhanced bioelectricity generation from sludge: From modular optimization to process performance.
Cai XL, Yao X, Yang XY, et al. · Synth Syst Biotechnol 2027
- Optimizing nonlinear absorption via modulating π-electron delocalization in multi-ring conjugated cores: from TPA at 515/650 nm to broad temporal response.
Jia J, Liu J, Lu Y, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- A strengths-based resilience intervention for first-year nursing students: A mixed-methods quasi-experimental evaluation of short-term outcomes.
Na Nakorn S, Chandler GE, Chung J, et al. · Nurse Educ Today 2027
- Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.
Vachhani P, Repp J, Hamer-Maansson JE, et al. · Hematology 2026
- Impact of temperature and ion concentration on optical properties of Sm3+-doped KLaSiO4 phosphors.
Komar J, Rebrova N, Lisiecki R · Spectrochim Acta A Mol Biomol Spectrosc 2026
- A Proposal to Make Mars Sample Return a Collaborative NASA, ESA, and CNSA Effort.
Li YL · Astrobiology 2026
Also in development for Anemia Due to Chronic Kidney Disease
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.